Core Viewpoint - The company has submitted a clinical trial application for its self-developed siRNA drug FB7013, targeting the MASP-2 protein, for the treatment of primary IgA nephropathy, marking it as the first-in-class drug in this category [1][2]. Drug Registration Clinical Trial Application - Product Name: FB7013 Injection - Application Matter: Domestic production drug registration clinical trial - Indication: Intended for the treatment of primary IgA nephropathy - Approval Conclusion: The application has been accepted according to the Administrative Licensing Law of the People's Republic of China [1]. Drug Mechanism - FB7013 is the first siRNA drug globally to target the MASP-2 protein, with potential for first-in-class status. It aims to inhibit MASP-2 activity to block the abnormal activation of the lectin pathway, thereby reducing complement-mediated kidney tissue damage. Future applications may extend to diseases related to complement activation, such as membranous nephropathy and diabetic nephropathy [2]. Preclinical Research Data - In healthy crab-eating macaques, FB7013 demonstrated strong and lasting inhibition of the target protein, achieving over 95% knockdown of serum MASP-2 protein after a single subcutaneous injection, with over 90% knockdown maintained for 105 days. This suggests potential for administration every 3-6 months in clinical settings, enhancing patient compliance. In IgA nephropathy models, FB7013 showed significant efficacy and good safety profile, with dose-dependent reductions in urinary protein levels and increases in glomerular filtration rate. High-dose treatment for 8 weeks resulted in a 36% reduction in mesangial cell numbers and a 43% reduction in IgA deposition. No significant off-target risks were identified [3]. Potential Market Outlook - IgA nephropathy is one of the most common primary glomerular diseases globally, characterized by abnormal deposition of IgA immune complexes in the glomeruli, leading to chronic kidney failure. According to Frost & Sullivan, the number of IgA nephropathy patients increased from 8.8 million in 2015 to 9.3 million in 2020, and is expected to reach 10.2 million by 2030. The global market for IgA nephropathy treatment drugs is projected to grow from $567 million in 2020 to $1.196 billion by 2025, with a compound annual growth rate of 16.1%, indicating significant market potential [5].

Core Viewpoint - Frontier Biotech's siRNA drug FB7013 has received clinical trial approval from the National Medical Products Administration, marking a significant milestone in the treatment of IgA nephropathy [1][2] Company Summary - FB7013 is the world's first siRNA drug targeting the key protein MASP-2 in the complement lectin pathway, developed independently by Frontier Biotech [1] - The drug aims to treat primary immunoglobulin A nephropathy (IgA nephropathy) by specifically inhibiting MASP-2, thereby reducing complement-mediated kidney tissue damage [1] - Clinical pre-research indicates that a single subcutaneous injection in healthy monkeys resulted in over 95% reduction of serum MASP-2 protein, with effects lasting over 105 days [1] - The drug shows significant dose-dependent efficacy in IgA nephropathy models, with improvements in urinary protein levels and kidney function [1] - The clinical trial approval is a crucial step for Frontier Biotech in establishing itself as a competitive player in the global siRNA innovation market [2] Industry Summary - The global IgA nephropathy patient population is projected to reach 10.2 million by 2030, with the treatment market expected to grow from $567 million in 2020 to $1.196 billion by 2025, reflecting a compound annual growth rate of 16.1% [2] - Current treatments primarily involve corticosteroids and immunosuppressants, which have limited efficacy and significant side effects [2] - If successful, FB7013 could provide a new treatment option for IgA nephropathy and potentially expand to other diseases related to complement pathway abnormalities, such as membranous nephropathy and diabetic nephropathy [2]

Group 1: Innovation in Pharmaceuticals - In 2025, China approved a record 76 innovative drugs, significantly surpassing the 48 approved in 2024, marking a historical high [1] - The total amount of foreign licensing transactions for innovative drugs in China exceeded $130 billion in 2025, with over 150 transactions, also a historical high [1] - Among the 76 approved innovative drugs, 47 are chemical drugs, 23 are biological products, and 6 are traditional Chinese medicines, with a high proportion of domestic innovations [1] Group 2: Drug Approval and Clinical Trials - China Medical's subsidiary Tianfang Pharmaceutical received approval for clarithromycin tablets, which passed the consistency evaluation for generic drugs [2] - Microchip Biotech announced that its CS08399 tablets for treating tumors with MTAP deficiency have had their clinical trial application accepted [3] - Frontier Biotech's FB7013 injection, targeting MASP-2 for IgA nephropathy, received acceptance for its clinical trial application, marking it as a first-in-class drug [4] Group 3: Capital Market Activities - Yifang Biotechnology submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as the exclusive sponsor [5] - Wanyi Medical also submitted a listing application to the Hong Kong Stock Exchange, with Guotai Junan International as the exclusive sponsor [6] Group 4: Corporate Investments and Acquisitions - Yunnan Baiyao plans to invest up to 45% of its net assets in financial products in 2026 [7] - Haili Biological's subsidiary intends to acquire 51% stakes in seven dental chain companies for 61.2 million yuan, expecting to increase revenue by approximately 100 million yuan [9] Group 5: Corporate Restructuring and Legal Matters - *ST Chang Pharmaceutical announced that its restructuring investors intend to terminate the restructuring investment agreement [10] - Zai Lab entered a global strategic cooperation and licensing agreement with AbbVie for the development and commercialization of ZG006, with potential milestone payments totaling up to $10.75 billion [11] - Tianyu Biotech's actual controller received a notice from the China Securities Regulatory Commission regarding an investigation into alleged illegal stock reduction [13]

Core Viewpoint - Frontier Biotech (688221.SH) has submitted a clinical trial application for its self-developed siRNA drug targeting the MASP-2 protein, aimed at treating primary immunoglobulin A nephropathy (IgA nephropathy) [1] Group 1 - The clinical trial application for the drug, named FB7013 injection, was submitted to the National Medical Products Administration on December 22, 2025 [1] - On December 31, 2025, the company received a notice of acceptance from the National Medical Products Administration for the clinical trial application of FB7013 [1] - The drug is specifically intended for the treatment of primary immunoglobulin A nephropathy (IgA nephropathy) [1]

Core Viewpoint - Frontier Biotech (688221.SH) has submitted a clinical trial application for FB7013, a siRNA drug targeting the MASP-2 protein, aimed at treating primary immunoglobulin A nephropathy (IgA nephropathy), marking it as the first-in-class drug in this category [1] Group 1 - The clinical trial application was submitted to the National Medical Products Administration on December 22, 2025, and the acceptance notice was received on December 31, 2025 [1] - FB7013 demonstrates strong and sustained inhibition of the target protein in healthy crab-eating macaques and shows clear efficacy in a crab-eating macaque model of IgA nephropathy, with good safety profile [1] - This drug represents a significant advancement as it is the first globally to target the MASP-2 protein with siRNA technology [1]

Core Viewpoint - The company has submitted a clinical trial application for its self-developed siRNA drug FB7013 targeting the MASP-2 protein, which is intended for the treatment of primary immunoglobulin A nephropathy (IgA nephropathy) [1] Group 1 - The clinical trial application was submitted to the National Medical Products Administration on December 22, 2025, and the acceptance notice was received on December 31, 2025 [1] - FB7013 is the world's first siRNA drug targeting the MASP-2 protein to apply for clinical trials, indicating its potential as a first-in-class treatment [1]